Allergan Plc (AGN)

153.53
0.14 0.09
NYSE : Health Technology
Prev Close 153.67
Open 153.37
Day Low/High 152.31 / 155.51
52 Wk Low/High 125.84 / 197.00
Volume 1.79M
Avg Volume 3.08M
Exchange NYSE
Shares Outstanding 332.61M
Market Cap 51.26B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.88%)

Latest News

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Allergan Announces FDA Acceptance Of New Drug Application For Ubrogepant For The Acute Treatment Of Migraine

Allergan Announces FDA Acceptance Of New Drug Application For Ubrogepant For The Acute Treatment Of Migraine

- Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine -

Watching Shares of Och-Ziff Capital Management

Watching Shares of Och-Ziff Capital Management

With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

Jim Cramer's watching six stocks to determine when the selling will end.

Could Kroger Lose the Grocery Wars Over This Challenge?

Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan wants Botox licenses for pediatric patients.

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.

Allergan Announces Phase 3 Results For Rapastinel As An Adjunctive Treatment Of Major Depressive Disorder (MDD)

Allergan Announces Phase 3 Results For Rapastinel As An Adjunctive Treatment Of Major Depressive Disorder (MDD)

-- Three acute pivotal studies did not meet their primary endpoint --

Allergan To Present At The Cowen And Company 39th Annual Health Care Conference

Allergan To Present At The Cowen And Company 39th Annual Health Care Conference

DUBLIN, March 4, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Cowen and Company 39 th Annual Health Care...

Allergan Presents Data From Seven Abstracts At The 2019 American Academy Of Dermatology (AAD) In Washington D.C.

Allergan Presents Data From Seven Abstracts At The 2019 American Academy Of Dermatology (AAD) In Washington D.C.

DUBLIN, March 1, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington D.

Allergan Responds To Public Shareholder Letter

Allergan Responds To Public Shareholder Letter

DUBLIN, Feb. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today issued the following statement from its Board of Directors in response to a public shareholder letter: "While we appreciate the input of Appaloosa as we do all of our shareholders, we...

Robert J. Hugin Appointed To Allergan Board Of Directors

Robert J. Hugin Appointed To Allergan Board Of Directors

- Sixth New Director Since 2017 as Part of Allergan's Transformation from a Generic to a Branded Biopharmaceutical Company -

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Allergan To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Allergan To Present At The 8th Annual SVB Leerink Global Healthcare Conference

DUBLIN, Feb. 15, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 8 th Annual SVB Leerink Global Healthcare...

Aegon Reports Second Half 2018 Results

Aegon Reports Second Half 2018 Results

Net income declines to EUR 253 million reflecting unfavorable market movements and other charges Underlying earnings decrease by 8% to EUR 1,010 million, as lower Retirement Plans earnings in the US more than offset business growth and higher margins in...

Aegon To Grow Capital Generation And Dividends

Aegon To Grow Capital Generation And Dividends

Aegon has set new medium-term financial targets with a focus on growing capital generation and dividends.

Evolus Stockholders May Be Frowning in the Short Run

Evolus Stockholders May Be Frowning in the Short Run

Shares of the Botox competitor could correct/consolidate after a recent surge.

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.

When Everyone Sees the Obvious the Obvious Rarely Happens

Right now it feels as though everyone sees the obvious resistance and overbought situation.

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Shares of Botox maker Allergan slipped after a billionaire hedge-fund manager challenges the company's management.

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Evolus surges Monday after the U.S. Food and Drug Administration approves the company's new wrinkle treatment for adult patients which is expected to be a key rival to Allergan's Botox.

ALLERGAN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.

A Pharma Giant, an Airline and Other Stocks That Look Good Short

AGN, AVA, ALK, RLI and CRT all recently were downgraded by TheStreet's Quant Ratings.

TheStreet Quant Rating: D+ (Sell)